title: How will HPV vaccines affect cervical cancer?
abstract: Cancer of the uterine cervix is the second largest cause of cancer deaths in women, and its toll is greatest in populations that lack screening programmes to detect precursor lesions. Persistent infection with 'high risk' genotypes of human papillomavirus (HPV) is necessary, although not sufficient, to cause cervical carcinoma. Therefore, HPV vaccination provides an opportunity to profoundly affect cervical cancer incidence worldwide. A recently licensed HPV subunit vaccine protects women from a high proportion of precursor lesions of cervical carcinoma and most genital warts. Here we examine the ramifications and remaining questions that surround preventive HPV vaccines.
authors.affiliation: Department of Pathology, The Johns Hopkins University, Baltimore, Maryland 21231, USA. roden@jhmi.edu
authors.forename: Richard
authors.initials: R
authors.lastname: Roden
authors.forename: T-C
authors.initials: TC
authors.lastname: Wu
mesh_terms: D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D027383:Papillomaviridae / Q000276:immunology*; D030361:Papillomavirus Infections / Q000517:prevention & control* / Q000821:virology; D053918:Papillomavirus Vaccines; D002583:Uterine Cervical Neoplasms / Q000517:prevention & control* / Q000821:virology; D014611:Vaccination; D014765:Viral Vaccines / Q000008:administration & dosage*
chemical_list: D053918:Papillomavirus Vaccines; D014765:Viral Vaccines